SG158143A1 - Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders - Google Patents

Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders

Info

Publication number: SG158143A1
Authority: SG; Singapore
Prior art keywords: proliferative; inflammatory disorders; neurological; treatment; compounds
Prior art date: 2004-12-20

Application number

SG200908383-3A

Other languages

English (en)

Inventor

Edmund Idris Graziani

Kevin Pong

Jerauld Skotnicki

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-20

Filing date

2005-12-15

Publication date

2010-01-29

2005-12-15 Application filed by Wyeth Corp filed Critical Wyeth Corp

2010-01-29 Publication of SG158143A1 publication Critical patent/SG158143A1/en

Links

208000027866 inflammatory disease Diseases 0.000 title abstract 2
230000002062 proliferating effect Effects 0.000 title abstract 2
230000000926 neurological effect Effects 0.000 title 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000012902 Nervous system disease Diseases 0.000 abstract 2
201000009030 Carcinoma Diseases 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
208000031481 Pathologic Constriction Diseases 0.000 abstract 1
208000009956 adenocarcinoma Diseases 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000003018 neuroregenerative effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG200908383-3A 2004-12-20 2005-12-15 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders SG158143A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US63766604P	2004-12-20	2004-12-20

Publications (1)

Publication Number	Publication Date
SG158143A1 true SG158143A1 (en)	2010-01-29

Family

ID=36087657

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200908383-3A SG158143A1 (en)	2004-12-20	2005-12-15	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders

Country Status (26)

Country	Link
US (5)	US7276498B2 (de)
EP (1)	EP1828202B1 (de)
JP (1)	JP5094406B2 (de)
KR (1)	KR20070090913A (de)
CN (1)	CN101084227B (de)
AR (1)	AR052269A1 (de)
AT (1)	ATE549342T1 (de)
AU (1)	AU2005319454B2 (de)
BR (1)	BRPI0519495A2 (de)
CA (1)	CA2590155A1 (de)
CR (1)	CR9148A (de)
DK (1)	DK1828202T3 (de)
ES (1)	ES2380779T3 (de)
GT (1)	GT200500368A (de)
HN (1)	HN2005035605A (de)
IL (1)	IL183664A (de)
MX (1)	MX2007007408A (de)
NI (1)	NI200700157A (de)
NO (1)	NO20072664L (de)
NZ (1)	NZ574663A (de)
PE (1)	PE20060765A1 (de)
RU (1)	RU2394036C2 (de)
SG (1)	SG158143A1 (de)
TW (1)	TW200628152A (de)
UA (1)	UA94034C2 (de)
WO (1)	WO2006068932A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003254168A1 (en)	2002-07-30	2004-02-16	Wyeth	Parenteral formulations containing a rapamycin hydroxyester
EP1720886A1 (de) *	2004-03-02	2006-11-15	Wyeth	Makrolide und verfahren zu deren herstellung
US7507752B2 (en) *	2004-06-03	2009-03-24	Wyeth	Biosynthetic gene cluster for the production of a complex polyketide
RU2007119585A (ru) *	2004-12-20	2009-01-27	Вайет (Us)	Производные рапамицина и их применение при лечении неврологических заболеваний
SG158143A1 (en) *	2004-12-20	2010-01-29	Wyeth Corp	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
KR20080077618A (ko) *	2005-12-07	2008-08-25	와이어쓰	정제된 결정체 ｃｃｉ-779 의 제조 방법
RU2008120712A (ru) *	2005-12-07	2010-01-20	Вайет (Us)	Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
RU2008120670A (ru) *	2005-12-07	2010-01-20	Вайет (Us)	Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
KR20080099317A (ko)	2006-03-07	2008-11-12	와이어쓰	신경퇴행성 질환 치료를 위한 메리다마이신 유사체
RU2010104916A (ru) *	2006-08-16	2011-08-20	Михаил В. Благосклонный (US)	Способ профилактики и лечения возрастных заболеваний
TW200824713A (en) *	2006-10-18	2008-06-16	Wyeth Corp	Processes for the synthesis of individual isomers of mono-PEG CCI-779
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080175887A1 (en)	2006-11-20	2008-07-24	Lixiao Wang	Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
CA2676613A1 (en) *	2007-01-29	2008-08-07	Wyeth	Immunophilin ligands and methods for modulating immunophilin and calcium channel activity
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2009045370A2 (en)	2007-09-28	2009-04-09	Intrexon Corporation	Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2009100214A2 (en) *	2008-02-05	2009-08-13	The Johns Hopkins University	Induction of thyroid iodide-handling gene expression in human cancers
WO2009105510A1 (en) *	2008-02-19	2009-08-27	Wyeth	Methods for using rapamycin analogues in the treatment of neurological disorders
WO2010024898A2 (en)	2008-08-29	2010-03-04	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
PT2365802T (pt)	2008-11-11	2017-11-14	Univ Texas	Microcápsulas de rapamicina e utilização para o tratamento de cancro
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
KR20130128018A (ko) *	2009-04-10	2013-11-25	하이얀 치	새로운 노화 방지 물질 및 그 확인 방법
US20170079962A1 (en)	2009-11-11	2017-03-23	Rapamycin Holdings, Llc	Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US20130195800A1 (en)	2010-03-23	2013-08-01	Intrexon Corporation	Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
ES2372077B2 (es) *	2010-06-24	2012-05-18	Universidad De Sevilla	Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down.
EP2446886A1 (de) *	2010-10-29	2012-05-02	Fondazione Telethon	Autophagieregulierer und ihre Verwendungen beim der Behandlung von Kollagen-VI-gestörten Muskeldystrophien
US9402919B2 (en)	2011-03-04	2016-08-02	Intrexon Corporation	Vectors conditionally expressing protein
EP2589383A1 (de)	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
WO2014059295A1 (en)	2012-10-12	2014-04-17	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
ITMI20122065A1 (it) *	2012-12-03	2014-06-04	Univ Padova	Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
GB2538747B (en) *	2015-05-27	2022-04-13	Airbus Operations Ltd	A measuring apparatus for measuring properties of a surface
JP6871919B2 (ja)	2015-06-16	2021-05-19	ナノファギックスエルエルシー	薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
UY37343A (es)	2016-07-25	2018-02-28	Intrexon Corp	Control del fenotipo en plantas
US11116852B2 (en)	2016-11-09	2021-09-14	Precigen, Inc.	Frataxin expression constructs
EP3848065B1 (de)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
WO2020076738A2 (en) *	2018-10-12	2020-04-16	Bellicum Pharmaceuticals, Inc	Protein-binding compounds
JP7262581B2 (ja)	2018-11-14	2023-04-21	ルトニックス，インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
EP4272825A3 (de)	2019-01-22	2023-12-06	Aeovian Pharmaceuticals, Inc.	Mtorc-1-modulatoren und verwendungen davon
JP7487228B2 (ja)	2019-04-08	2024-05-20	バード・ペリフェラル・バスキュラー・インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
CN116322677B (zh) *	2020-07-21	2025-09-23	艾奥维安制药公司	Mtorc1调节剂及其用途
CN114306330A (zh) *	2022-01-27	2022-04-12	中以海德人工智能药物研发股份有限公司	雷帕霉素在治疗或预防乙型肝炎中的应用
GB202415232D0 (en)	2024-10-16	2024-11-27	Nacamed As	Composition

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1445742A1 (de) *	1963-11-06	1968-12-19	Bayer Ag	Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
DE1545824A1 (de)	1965-06-21	1969-12-11	Bayer Ag	Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen
CA930734A (en) *	1969-08-11	1973-07-24	Bickel Hans	Antibiotically active rifamycin compounds and processes for their manufacture
US3686238A (en) *	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3900465A (en) *	1973-04-05	1975-08-19	Lepetit Spa	3-formylrifamycin azines
US3905981A (en) *	1973-10-12	1975-09-16	Research Corp	N-dealkylation of tertiary amines
US4127720A (en) *	1977-09-21	1978-11-28	Bristol-Myers Company	Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity
JPH0262875A (ja)	1988-05-23	1990-03-02	Wakunaga Pharmaceut Co Ltd	新規イソインドリン誘導体
WO1991019495A1 (en)	1990-06-11	1991-12-26	Fujisawa Pharmaceutical Co., Ltd.	Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
DE4021404A1 (de)	1990-07-05	1992-01-09	Sandoz Ag	Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5023262A (en) *	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
GB2249027A (en)	1990-10-23	1992-04-29	Fujisawa Pharmaceutical Co	Use of macrolide compounds for hepatic failure
WO1992013862A1 (en)	1991-02-05	1992-08-20	Fujisawa Pharmaceutical Co., Ltd.	Lactone compounds
CA2103454C (en)	1991-09-05	2004-11-02	Jay R. Luly	Macrocyclic immunomodulators
US5604294A (en) *	1991-09-05	1997-02-18	Luly; Jay R.	Macrocyclic immunomodulators
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
ES2295093T3 (es)	1993-04-23	2008-04-16	Wyeth	Conjugados y anticuerpos de rapamicina.
US7279561B1 (en) *	1993-04-23	2007-10-09	Wyeth	Anti-rapamycin monoclonal antibodies
US5798355A (en)	1995-06-07	1998-08-25	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity
US5525610A (en) *	1994-03-31	1996-06-11	American Home Products Corporation	42-Epi-rapamycin and pharmaceutical compositions thereof
US5696135A (en) *	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
CZ292233B6 (cs) *	1995-06-09	2003-08-13	Novartis Ag	Deriváty rapamycinu a jejich použití jako léčiv
TW427904B (en) *	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
US5717092A (en) *	1996-03-29	1998-02-10	Vertex Pharmaceuticals Inc.	Compounds with improved multi-drug resistance activity
US5780484A (en) *	1996-11-13	1998-07-14	Vertex Pharmaceuticals Incorporated	Methods for stimulating neurite growth with piperidine compounds
US6187784B1 (en) *	1998-06-03	2001-02-13	Gpi Nil Holdings, Inc.	Pipecolic acid derivative hair growth compositions and uses
EP1083872A1 (de)	1998-06-03	2001-03-21	GPI NIL Holdings, Inc.	Haarwuchszusammensetzungen basierend auf pipekolinsäurederivaten
US6376517B1 (en)	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
US6015809A (en) *	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
WO2000009510A1 (en)	1998-08-17	2000-02-24	American Home Products Corporation	Photocyclized rapamycins
US6316436B1 (en)	1998-12-08	2001-11-13	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
CA2384151A1 (en)	1999-09-09	2001-03-15	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6569867B2 (en) *	1999-10-01	2003-05-27	Kosan Biosciences, Inc.	Polyketide derivatives
ATE356880T1 (de)	1999-10-29	2007-04-15	Kosan Biosciences Inc	Rapamycin analoge
CA2407259A1 (en)	2000-05-17	2001-11-22	Chaitan Khosla	Polyketide derivatives
EP1419154B1 (de)	2001-08-22	2005-10-05	Wyeth	Rapanycin29-enole
CA2455311A1 (en)	2001-08-22	2003-03-06	Wyeth	Rapamycin dialdehydes
ES2296063T3 (es)	2002-07-16	2008-04-16	Biotica Technology Limited	Produccion de poliquetidos y otros productos naturales.
DE102004049700B4 (de)	2004-10-12	2007-10-18	Aircabin Gmbh	Kraftunterstützungsvorrichtung mit lastabhängiger Kraftunterstützung
SG158143A1 (en) *	2004-12-20	2010-01-29	Wyeth Corp	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
RU2007119585A (ru)	2004-12-20	2009-01-27	Вайет (Us)	Производные рапамицина и их применение при лечении неврологических заболеваний
KR20080099317A (ko) *	2006-03-07	2008-11-12	와이어쓰	신경퇴행성 질환 치료를 위한 메리다마이신 유사체

2005
- 2005-12-15 SG SG200908383-3A patent/SG158143A1/en unknown
- 2005-12-15 JP JP2007546925A patent/JP5094406B2/ja not_active Expired - Fee Related
- 2005-12-15 EP EP05849447A patent/EP1828202B1/de not_active Expired - Lifetime
- 2005-12-15 AR ARP050105290A patent/AR052269A1/es not_active Application Discontinuation
- 2005-12-15 BR BRPI0519495-4A patent/BRPI0519495A2/pt not_active IP Right Cessation
- 2005-12-15 KR KR1020077013082A patent/KR20070090913A/ko not_active Ceased
- 2005-12-15 RU RU2007119584/04A patent/RU2394036C2/ru not_active IP Right Cessation
- 2005-12-15 AU AU2005319454A patent/AU2005319454B2/en not_active Expired - Fee Related
- 2005-12-15 CA CA002590155A patent/CA2590155A1/en not_active Abandoned
- 2005-12-15 ES ES05849447T patent/ES2380779T3/es not_active Expired - Lifetime
- 2005-12-15 HN HN2005035605A patent/HN2005035605A/es unknown
- 2005-12-15 WO PCT/US2005/045551 patent/WO2006068932A2/en not_active Ceased
- 2005-12-15 GT GT200500368A patent/GT200500368A/es unknown
- 2005-12-15 DK DK05849447.7T patent/DK1828202T3/da active
- 2005-12-15 TW TW094144448A patent/TW200628152A/zh unknown
- 2005-12-15 MX MX2007007408A patent/MX2007007408A/es active IP Right Grant
- 2005-12-15 UA UAA200706849A patent/UA94034C2/ru unknown
- 2005-12-15 PE PE2005001466A patent/PE20060765A1/es not_active Application Discontinuation
- 2005-12-15 US US11/300,839 patent/US7276498B2/en not_active Expired - Fee Related
- 2005-12-15 NZ NZ574663A patent/NZ574663A/en not_active IP Right Cessation
- 2005-12-15 AT AT05849447T patent/ATE549342T1/de active
- 2005-12-15 CN CN2005800437154A patent/CN101084227B/zh not_active Expired - Fee Related
2007
- 2007-01-26 US US11/698,504 patent/US7560457B2/en not_active Expired - Fee Related
- 2007-05-24 CR CR9148A patent/CR9148A/es not_active Application Discontinuation
- 2007-05-25 NO NO20072664A patent/NO20072664L/no not_active Application Discontinuation
- 2007-06-04 IL IL183664A patent/IL183664A/en not_active IP Right Cessation
- 2007-06-18 NI NI200700157A patent/NI200700157A/es unknown
- 2007-08-14 US US11/893,090 patent/US7470682B2/en not_active Expired - Fee Related
2008
- 2008-11-24 US US12/276,668 patent/US20090203682A1/en not_active Abandoned
2009
- 2009-06-09 US US12/481,211 patent/US7795252B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL183664A (en)	2012-06-28
TW200628152A (en)	2006-08-16
GT200500368A (es)	2006-07-13
RU2394036C2 (ru)	2010-07-10
CA2590155A1 (en)	2006-06-29
US20060135549A1 (en)	2006-06-22
MX2007007408A (es)	2007-07-12
BRPI0519495A2 (pt)	2009-02-03
WO2006068932A2 (en)	2006-06-29
AU2005319454A1 (en)	2006-06-29
CR9148A (es)	2007-11-23
UA94034C2 (ru)	2011-04-11
US20090203682A1 (en)	2009-08-13
EP1828202B1 (de)	2012-03-14
HN2005035605A (es)	2010-08-05
ES2380779T3 (es)	2012-05-18
WO2006068932A3 (en)	2006-10-19
US7470682B2 (en)	2008-12-30
CN101084227A (zh)	2007-12-05
JP5094406B2 (ja)	2012-12-12
NZ574663A (en)	2010-05-28
US20090239855A1 (en)	2009-09-24
US20070142423A1 (en)	2007-06-21
AR052269A1 (es)	2007-03-07
IL183664A0 (en)	2007-09-20
ATE549342T1 (de)	2012-03-15
JP2008524240A (ja)	2008-07-10
US7795252B2 (en)	2010-09-14
US20080004264A1 (en)	2008-01-03
NI200700157A (es)	2008-04-21
US7276498B2 (en)	2007-10-02
HK1108442A1 (en)	2008-05-09
CN101084227B (zh)	2011-11-16
US7560457B2 (en)	2009-07-14
RU2007119584A (ru)	2009-01-27
PE20060765A1 (es)	2006-10-02
NO20072664L (no)	2007-06-25
EP1828202A2 (de)	2007-09-05
KR20070090913A (ko)	2007-09-06
AU2005319454B2 (en)	2012-08-09
DK1828202T3 (da)	2012-05-07

Publication	Publication Date	Title
MX2007007408A (es)	2007-07-12	Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios.
MX2007007409A (es)	2007-07-12	Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
GB2463833A (en)	2010-03-31	Methods and compositions for the treatment of neurological disorders
NO20091661L (no)	2009-06-02	Anvendelse av pegylert IL-10 for a behandle kreft
EA200900662A1 (ru)	2009-12-30	Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
DE60329756D1 (de)	2009-12-03	Mitotische kinesin-hemmer
TW200800976A (en)	2008-01-01	New compounds for the treatment of neurological, psychiatric or pain disorders
DK1450799T3 (da)	2007-03-19	Arylurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
MX2007002398A (es)	2007-05-15	Nuevas composiciones farmaceuticas para el tratamiento de cancer.
WO2005013996A3 (en)	2005-06-09	2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
DE60231439D1 (de)	2009-04-16	Mitotische kinesinhemmer
DE60234278D1 (de)	2009-12-17	Mitotische kinesin-hemmer
ATE427759T1 (de)	2009-04-15	Behandlung von fettsucht und verbundenen erkrankungen
CY1112397T1 (el)	2015-12-09	Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
MY142988A (en)	2011-02-14	Novel aminobenzophenone compounds
MA29266B1 (fr)	2008-02-01	Traitement de tumeurs metastatiques
ECSP066986A (es)	2006-12-29	Beta-carbolinas utiles para tratar enfermedades inflamatorias
DK1463735T3 (da)	2009-12-14	Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
WO2006069253A3 (en)	2007-08-02	Trefoil factors and methods of treating proliferation disorders using same
WO2008042435A3 (en)	2008-07-24	Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
TW200706536A (en)	2007-02-16	Indole compounds
ECSP077390A (es)	2007-05-30	Uso de epotilonas en el tratamiento de metástasis en hueso y tumores o tipos de cancer en hueso
WO2009135939A3 (en)	2010-04-29	Pm02734 for use in the treatment of ewing' s sarcoma, osteosarcoma, rhabdomyosarcoma and medulloblastoma